Blog - Detail Page

Once prescribed almost exclusively to patients with type 2 diabetes to help control their blood sugar, GLP-1 receptor agonists, now widely recognized by brand names such as Ozempic, Wegovy, and Mounjaro, have quickly expanded beyond endocrinology clinics to become the main topic of discourse throughout the world about weight loss, obesity, and metabolic health. What started as a medical breakthrough in diabetes has become a powerful tool that is changing the way we think about weight loss medically, socially, and ethically.

As demand rises among a wide range of people, it is important to understand not only how these drugs work but also why their use has grown so quickly, who really benefits from them, and the risks that may arise when medical innovation outpaces public understanding.

What are GLP-1 receptor agonists?

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that helps control appetite and blood sugar levels. GLP-1 receptor agonists are drugs that mimic this hormone to help control blood sugar levels and, most importantly, reduce appetite and calorie intake. Researchers have found that these effects can lead to clinically meaningful weight loss over time, especially when combined with structured lifestyle support.

Different Types of Incretin-Based Weight-Loss Medications and the Newcomer Retatrutide

Not all GLP-1 medications are the same. Some therapies are single-agonists (GLP-1 receptor agonists), such as semaglutide (Ozempic/Wegovy), while newer options like tirzepatide (Mounjaro/Zepbound) act as dual agonists targeting both GIP and GLP-1, which may produce greater average weight loss in clinical trials. Even more advanced agents are now emerging, including retatrutide, a triple-hormone receptor agonist (GIP/GLP-1/glucagon). Early clinical trial findings suggest retatrutide may lead to substantial weight reduction, marking a new frontier in obesity pharmacotherapy. However, longer-term safety and real-world outcomes are still being established.

What makes retatrutide especially interesting is its additional glucagon receptor activity, which may support higher energy expenditure (calorie burning) alongside appetite reduction, potentially contributing to greater weight loss than older single or dual-agonist therapies.

From Diabetes Treatment to Weight Management: What Changed?

The change happened when clinical trials started to show that people who were overweight or obese lost a lot of weight. One of the landmark studies, the STEP 1 trial, showed that once-weekly semaglutide 2.4 mg resulted in substantial weight loss when combined with lifestyle intervention. This was a turning point in obesity medicine because the magnitude of effect was greater than that seen with many traditional weight-loss medications.

In addition, newer agents, such as tirzepatide (a dual GIP/GLP-1 receptor agonist), showed even greater average weight reduction in adults with obesity, further strengthening the role of incretin-based therapy in long-term weight management.

In addition to weight change, evidence has also extended to more general cardiometabolic outcomes. For instance, semaglutide 2.4 mg has been examined in individuals with overweight/obesity and pre-existing cardiovascular disease without diabetes, yielding results that indicate its potential significance beyond mere weight reduction.

Why has the use of GLP-1 grown so quickly?

Several things are causing the rise:

1. Clinical effectiveness: The weight loss seen in trials is significant and has changed both how doctors treat patients and what patients expect.
2. Growing recognition of obesity as a disease: Obesity is no longer viewed simply as a willpower issue. It is increasingly treated as a complex condition requiring multi-level medical, nutritional, and behavioral support.
3. ‘Spillover demand’ and public awareness: While awareness can improve help-seeking behavior, it can also spread misinformation, especially when these medications are discussed as quick fixes rather than medical therapies requiring professional oversight.

Who gets the most out of this, and who should be careful?

GLP-1 receptor agonists can provide major benefits for individuals living with obesity, especially when associated with metabolic complications such as type 2 diabetes, insulin resistance, dyslipidemia, or hypertension.

However, these medications are not suitable for everyone. Semaglutide products used for long-term weight loss come with a warning about thyroid C-cell tumors found in rodents. They are also not safe for people who have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

This highlights an important message: GLP-1 medications should be used under medical supervision, in accordance with evidence-based criteria, and with proper screening and follow-up.

Side Effects and Long-Term Considerations

Many patients experience gastrointestinal side effects, like nausea, vomiting, diarrhea, constipation, or abdominal discomfort, especially when the dose is increased. Monitoring tolerability and safety is essential, especially in long-term use and in patients with comorbidities.

Another key issue is what happens when medication is stopped. Evidence suggests that many individuals experience partial weight regain after discontinuation, reinforcing that obesity management is often long-term and should be approached as ongoing care rather than a short-term intervention.

A growing worry: misuse, access without supervision, and products that are mixed

As demand has grown, so have the risks of using drugs without supervision, getting false information, and getting drugs illegally.

The American Diabetes Association has warned against using compounded GLP-1 (and dual GIP/GLP-1) products that the FDA has not approved because their contents, safety, quality, and effectiveness are unknown. This is important because the quality of medications and the accuracy of dosages are not small things; they have a direct impact on safety, outcomes, and trust in healthcare.

Conclusion: A Powerful Tool, Not a Shortcut

GLP-1 receptor agonists have transformed modern weight management and opened new possibilities for individuals living with obesity and metabolic disease. However, their rapid rise also highlights the importance of safe prescribing, accurate public awareness, and responsible use. When used appropriately under medical supervision and alongside healthy lifestyle changes, these medications can be powerful tools - not shortcuts - within a comprehensive care plan that prioritizes long-term health, sustainable outcomes, and overall well-being.

Dr. Nermin Moustafa (MD, PhD)
Assistant Professor of Human Nutrition and Dietetics
College of Health Sciences.